Navigation Links
Bradmer announces 2008 first quarter operational and financial results
Date:5/9/2008

the first patients in this trial and are pleased with our accomplishments of building a Phase III company in the last 18 months for less than $17 million dollars. The large expenses in developing the completed manufacturing process and ramping up toward the trial are behind us and we now go into the per patient costings as we execute this trial."

The Phase III trial will investigate Neuradiab as an adjuvant therapy to surgery, external beam radiation and temozolomide in 760 patients with newly diagnosed glioblastoma multiforme (GBM). The randomized trial is expected to be conducted at leading brain tumor treatment centers across the U.S.

Financial Highlights

Amounts in US dollars, unless specified otherwise, and results expressed in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

For the three-month period ended March 31, 2008, we recorded a net loss of $3,157,000, or $0.23 per common share based on the weighted average outstanding shares of 13,488,215. This compares to a net loss of $1,854,000, or $0.24 per common share for the three months ended March 31, 2007 based on the weighted average outstanding shares of 7,781,346. The increased loss in 2008 was primarily related to planned research and development spending with regard to the Company's lead clinical program, Neuradiab, in preparation for the proposed clinical trial, as well as the growth in the Company's administrative functions in anticipation of the clinical trial launch.

Research and development expenses for the first quarter of 2008 were $2,268,000, an increase of $864,000 from $1,404,000 in the same period of 2007. The increase was primarily due to increased costs associated with manufacturing and support for our Phase III clinical development program. The expenses incurred in 2008 were primarily related to amounts paid under drug manufacturing contracts of $1,382,000, as well as amounts paid to clinical and regulatory collaborators
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Bradmer announces new additions to management team
2. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
3. Notice of Bradmer Pharmaceuticals Conference Call
4. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
5. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
6. Bradmer announces additions to Scientific Advisory Board
7. Bradmer Medical Isotope Supply For Phase III Trial Secure
8. Bradmer to present at Rodman & Renshaw Healthcare Conference
9. Bradmer provides Phase III Neuradiab trial update and guidance
10. Bradmer announces management changes
11. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Tara Haelle HealthDay ... Binge drinking among young adult men may lead to increased ... drinking didn,t cause a similar rise in blood pressure for ... In fact, when young adult women drank lightly or moderately, ... the study found. "This finding parallels studies in older ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... 20, 2014 With a mere 19 ... Crist made a brief fundraising stop at the ... , Fresh from a debate last night with his ... stage for the first seven minutes because Crist had ... described the incident in one word: "weird." , Before ...
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 hc1.com ... a secure cloud solution that enables healthcare organizations ... the ultimate healthcare-specific customer relationship management (“CRM”) solution. ... the unique needs of the healthcare industry, the ... for providers and patients by combining healthcare CRM, ...
Breaking Medicine News(10 mins):Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2
... who are pre-, perimenopausal with dense breasts benefit most, ... For some women, digital mammography is a better bet ... Women under the age 50 with dense breasts who ... digital mammograms, said study author Dr. Etta Pisano, the ...
... its most selective filter to keep it from clogging with ... St. Louis reveal in a new study. , Researchers ... more vulnerable to dysfunction and disease. , "We speculate ... the filter that can damage it," says senior author Andrey ...
... Xoft, Inc., developer of the,Axxent(R) Electronic ... in,radiation oncology and non-invasive neurosurgery solutions, announced ... agreement., Under the agreement, Elekta will ... Electronic Brachytherapy in the radiation oncology,market. This ...
... Denver Museum of Nature & Science Reveals Plans for New $8 Million ... Interactive Health Science Exhibition ... Jan. 29 Beginning in April 2009, residents and,visitors to the Denver ... their health in ways they have never experienced at a museum,-- or ...
... ... Compliance, and Lowers Costs, NEWARK and EAST BRUNSWICK, N.J., ... empirical,data demonstrating the effectiveness of the Patient Centered Medical Home,(PC-MH), ... their personal physicians and -- when appropriate -- the,patient,s family. ...
... the American Roentgen Ray Society to add more journals ... , BioMed Central, the open access publisher of peer-reviewed ... 4,200 images to the GoldMiner collection. The collection now ... GoldMiner speeds your search for radiology images by quickly ...
Cached Medicine News:Health News:Digital Mammography Better Than Film for Some Women 2Health News:Digital Mammography Better Than Film for Some Women 3Health News:Breakdown of kidney's ability to clean its own filters likely causes disease 2Health News:Breakdown of kidney's ability to clean its own filters likely causes disease 3Health News:Xoft Signs Sales Development Agreement With Elekta 2Health News:Xoft Signs Sales Development Agreement With Elekta 3Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 2Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 3Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 4Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 5Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 6Health News:Ground Breaking Program Improves Diabetes Patient Outcomes 2Health News:Ground Breaking Program Improves Diabetes Patient Outcomes 3
(Date:10/22/2014)... CITY, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced that results from the  IAP310 study ... Pain Medicine (RAPM), a peer-reviewed journal with ... Phase 3 trial evaluating the safety and efficacy ... sublingual tablet system (SSTS), for the treatment of ...
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( ... pulmonology, today announced completion of enrollment in their RENEW ... Clinical Study is the FDA-approved IDE pivotal trial for ... emphysema. It was anticipated that the study, ... 2013, would take until the end of 2014 to ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
Vertigraft femoral shaft an large femoral cross-section designed primarily for use in lumbar corpectomy procedures. Freeze dried preservation....
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... fiber reinforced polymer material emulates the biomechanical ...
... bone graft substitute (beta-tricalcium ... Chronos is an advantageous ... It shortens operative time, ... quantity and quality of ...
... bone regeneration scaffold. Its ... composite ensures ideal osteoconductivity, ... structure maximizes permeability even ... the most meaningful measure ...
Medicine Products: